NeuroMetrix (NURO) Reports Q3 Loss of $0.26/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
NeuroMetrix Reports Q3 2015 Financial Results and Highlights
October 22, 2015 7:00 AM EDTApproximately 4,500 Quell® Devices Shipped, Up 73% Compared to Q2 2015 DPNCheck® Shipments at Three Year High of Nearly 40,000 Biosensors Revenue Up 44% to $2.1 Million Compared to Q3 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2015.
The Company operates in two markets - wearable therapeutic technology and point-of-care diagnostic tests. Its newest product is Quell, an over-the-counter wearable therapeutic device for chronic pain that was launched during the second quarter of 2015. Its... More
